Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.51 |
| ▸ | CA2 | P00918 | 19/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA5A | P35218 | 5/20 | 0.51 |
| ▸ | CA7 | P43166 | 5/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.51 |
| ▸ | CA4 | P22748 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596074 | 0.85 | NPC1 (0.58) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3613294 | 0.82 | CA1 (0.55) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3612871 | 0.82 | CA1 (0.55) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3608507 | 0.79 | CA1 (0.53) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3605049 | 0.79 | CA1 (0.50) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3160315 | 0.77 | CA1 (0.61) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL13119753 | 0.77 | CA1 (0.48) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3603208 | 0.74 | CA1 (0.54) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL3603224 | 0.73 | NPC1 (0.47) | CA1CA2CA12CA5ACA7 | |
| SCHEMBL4517904 | 0.73 | CA1 (0.49) | CA1CA2CA12CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | claimed |
| US-8080547-B2 | Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-12-20 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100041651-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-1912935-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041651-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES AND TRIAZOLOPYRIMIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, GLP1R, GLS | CA1 1232/4885CA2 338/4885CA12 2263/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | CA1 4588/4885CA2 4128/4885CA12 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.